Qilian International Holding Group Past Earnings Performance
Past criteria checks 0/6
Qilian International Holding Group's earnings have been declining at an average annual rate of -48.2%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been growing at an average rate of 4.3% per year.
Key information
-48.2%
Earnings growth rate
-49.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 4.3% |
| Return on equity | -18.3% |
| Net Margin | -16.7% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
The Market Doesn't Like What It Sees From Qilian International Holding Group Limited's (NASDAQ:QLI) Revenues Yet
May 02
Earnings Not Telling The Story For Qilian International Holding Group Limited (NASDAQ:QLI) After Shares Rise 79%
Dec 31Qilian International Non-GAAP EPS of $0.01, revenue of $32.09M
Oct 03We Think You Can Look Beyond Qilian International Holding Group's (NASDAQ:QLI) Lackluster Earnings
Sep 23Qilian International signs Gan Di Xin's exclusive distribution agreement
May 05Qilian International Holding Group Limited's (NASDAQ:QLI) Share Price Matching Investor Opinion
Apr 12Revenue & Expenses BreakdownBeta
How Qilian International Holding Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 46 | -8 | 4 | 1 |
| 30 Jun 23 | 54 | -3 | 4 | 1 |
| 31 Mar 23 | 62 | 1 | 3 | 1 |
| 31 Dec 22 | 63 | 1 | 3 | 1 |
| 30 Sep 22 | 65 | 1 | 3 | 1 |
| 30 Jun 22 | 62 | 1 | 3 | 1 |
| 31 Mar 22 | 59 | 1 | 3 | 0 |
| 31 Dec 21 | 58 | 2 | 3 | 0 |
| 30 Sep 21 | 57 | 3 | 3 | 0 |
| 30 Jun 21 | 55 | 3 | 3 | 0 |
| 31 Mar 21 | 52 | 4 | 3 | 0 |
| 31 Dec 20 | 51 | 4 | 3 | 0 |
| 30 Sep 20 | 50 | 5 | 3 | 0 |
| 30 Jun 20 | 48 | 5 | 3 | 0 |
| 31 Mar 20 | 47 | 5 | 3 | 0 |
| 31 Dec 19 | 46 | 5 | 3 | 0 |
| 30 Sep 19 | 46 | 5 | 4 | 0 |
| 30 Jun 19 | 49 | 6 | 3 | 0 |
| 31 Mar 19 | 52 | 7 | 3 | 0 |
| 31 Dec 18 | 51 | 6 | 3 | 0 |
| 30 Sep 18 | 50 | 5 | 2 | 0 |
| 30 Sep 17 | 23 | 1 | 2 | 0 |
Quality Earnings: QLI is currently unprofitable.
Growing Profit Margin: QLI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: QLI is unprofitable, and losses have increased over the past 5 years at a rate of 48.2% per year.
Accelerating Growth: Unable to compare QLI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: QLI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.5%).
Return on Equity
High ROE: QLI has a negative Return on Equity (-18.31%), as it is currently unprofitable.